学术交流 产品简介 诚征代理 联系我们 国内外进展 我们的服务



Br J Surg 2002 Nov;89(11):1396-401

Comment in:
· Br J Surg. 2003 Feb;90(2):248.

Cryotherapeutic ablation of liver tumours.

Sheen AJ, Poston GJ, Sherlock DJ.

Department of Surgery, North Manchester Healthcare NHS Trust, Manchester, UK.

BACKGROUND: This paper reports a 7-year experience of cryoablation for colorectal and non-colorectal liver metastases. METHODS: A retrospective review was undertaken of patients treated in two adjacent UK centres in the north-west of England. RESULTS: Over a 7-year period (1993-2000), 57 patients underwent cryotherapy for malignant hepatic tumours (41 colorectal, 16 non-colorectal). In the patients with colorectal metastases, preoperative carcinoembryonic antigen (CEA) levels fell significantly, from a mean of 444.1 to 6.22 micro g/l (P = 0.002). One patient died, two developed cryoshock and six had cardiorespiratory complications. All patients with colorectal metastases subsequently received 5-fluorouracil-based chemotherapy. The remaining 16 patients with non-colorectal tumours (seven neuroendocrine metastases, five hepatocellular carcinomas, three sarcomas, one cholangiocarcinoma) all received cryotherapy alone, with no major complications. The median survival for patients with non-colorectal metastases was 37 months, compared with 22 months for those with colorectal metastases (P = 0.005). CONCLUSION: Hepatic cryotherapy is effective and safe, as demonstrated by the significant reduction in postoperative CEA concentration and the low risk of complications. However, this initial short-term success was not reflected in 5-year survival rates. Cryotherapy for non-colorectal metastases had a greater long-term survival benefit and is a useful means of controlling symptoms.

Publication Types:
· Multicenter Study

PMID: 12390380 [PubMed - indexed for MEDLINE]

 

©2009 版权所有 中美医疗有限公司
e-mail: sino-usmed@cryocare.com.cn
设计制作:全程